Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Emixustat

Alternative Names: emixustat, acu-4429
Latest Update: 2024-05-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RPE65 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Stargardt Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kubota Vision
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Geographic Atrophy|Macular Degeneration|Stargardt Disease

Phase 2: Macular Degeneration|Geographic Atrophy|Stargardt Disease|Anetoderma|Diabetic Retinopathy

Phase 1: Healthy Volunteers|Geographic Atrophy|Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
The SeaSTAR Study (Safety and efficacy of EmixustAt in STARgardt disease)

P3

Unknown status

Stargardt Disease

2022-11-18

SeaSTAR

P3

Completed

Macular Degeneration|Stargardt Disease

2022-06-13

NCT02753400

P2

Completed

Diabetic Retinopathy

2017-11-01

NCT03033108

P2

Completed

Anetoderma|Stargardt Disease|Macular Degeneration

2017-11-01

Recent News Events

Date

Type

Title

10/04/2023

News Article

 Radiology Information Systems (RIS) Market to Notice Prominent USD 1,782.5 Million Growth by 2029

10/04/2023

News Article

 Smart Health Watches Market to Observe Prominent USD 185.63 Billion Growth by 2029

09/27/2023

PubMed

 Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease.

07/01/2023

PubMed

 Computational attributes of protein kinase-C gamma C2-domain & virtual screening for small molecules: elucidation from meta-dynamics simulations & free-energy calculations.

06/22/2023

PubMed

 Tuning the Metabolic Stability of Visual Cycle Modulators through Modification of an RPE65 Recognition Motif.

05/15/2023

News Article

 ABCA4 Retinopathy Therapeutics Market Will Register a CAGR of 18.6% from 2023 to 2031, says Growth Plus Reports

07/27/2022

News Article

 Kubota Vision Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions